AU2020343314A1 - Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels - Google Patents
Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels Download PDFInfo
- Publication number
- AU2020343314A1 AU2020343314A1 AU2020343314A AU2020343314A AU2020343314A1 AU 2020343314 A1 AU2020343314 A1 AU 2020343314A1 AU 2020343314 A AU2020343314 A AU 2020343314A AU 2020343314 A AU2020343314 A AU 2020343314A AU 2020343314 A1 AU2020343314 A1 AU 2020343314A1
- Authority
- AU
- Australia
- Prior art keywords
- levels
- thcy
- cbs
- pmol
- entirety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
- G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895230P | 2019-09-03 | 2019-09-03 | |
| US62/895,230 | 2019-09-03 | ||
| US202062983862P | 2020-03-02 | 2020-03-02 | |
| US62/983,862 | 2020-03-02 | ||
| PCT/US2020/049156 WO2021046190A1 (en) | 2019-09-03 | 2020-09-03 | Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020343314A1 true AU2020343314A1 (en) | 2022-03-24 |
Family
ID=74852233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020343314A Pending AU2020343314A1 (en) | 2019-09-03 | 2020-09-03 | Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220290116A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4025243A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022546550A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220091464A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114630673A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020343314A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022003539A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3152379A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290685A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022002571A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021046190A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9675678B2 (en) | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
| DK3998067T3 (da) | 2015-11-09 | 2024-10-28 | Univ Colorado Regents | Sammensætninger og fremgangsmåder til behandling af homocystinuri |
| CA3059592A1 (en) | 2017-04-17 | 2018-10-25 | The Regents Of The University Of Colorado, A Body Corporate | Optimization of enzyme replacement therapy for treatment of homocystinuria |
| MX2021015966A (es) | 2019-06-26 | 2022-04-06 | Travere Therapeutics Switzerland Gmbh | Producto farmacológico para terapia enzimática para el tratamiento de la homocistinuria. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9034318B2 (en) * | 2011-08-30 | 2015-05-19 | The Regents Of The University Of Colorado, A Body Corporate | Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria |
| US9675678B2 (en) * | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
| DK3998067T3 (da) * | 2015-11-09 | 2024-10-28 | Univ Colorado Regents | Sammensætninger og fremgangsmåder til behandling af homocystinuri |
| CA3059592A1 (en) * | 2017-04-17 | 2018-10-25 | The Regents Of The University Of Colorado, A Body Corporate | Optimization of enzyme replacement therapy for treatment of homocystinuria |
| MX2021015966A (es) * | 2019-06-26 | 2022-04-06 | Travere Therapeutics Switzerland Gmbh | Producto farmacológico para terapia enzimática para el tratamiento de la homocistinuria. |
-
2020
- 2020-09-03 EP EP20861108.7A patent/EP4025243A4/en active Pending
- 2020-09-03 KR KR1020227011039A patent/KR20220091464A/ko active Pending
- 2020-09-03 WO PCT/US2020/049156 patent/WO2021046190A1/en not_active Ceased
- 2020-09-03 BR BR112022003539A patent/BR112022003539A2/pt unknown
- 2020-09-03 JP JP2022514172A patent/JP2022546550A/ja active Pending
- 2020-09-03 CA CA3152379A patent/CA3152379A1/en active Pending
- 2020-09-03 AU AU2020343314A patent/AU2020343314A1/en active Pending
- 2020-09-03 CN CN202080076522.3A patent/CN114630673A/zh active Pending
- 2020-09-03 MX MX2022002571A patent/MX2022002571A/es unknown
- 2020-09-03 US US17/639,509 patent/US20220290116A1/en active Pending
-
2022
- 2022-02-17 IL IL290685A patent/IL290685A/en unknown
-
2025
- 2025-08-05 JP JP2025130469A patent/JP2025183204A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022002571A (es) | 2022-05-06 |
| KR20220091464A (ko) | 2022-06-30 |
| US20220290116A1 (en) | 2022-09-15 |
| WO2021046190A1 (en) | 2021-03-11 |
| EP4025243A1 (en) | 2022-07-13 |
| JP2022546550A (ja) | 2022-11-04 |
| JP2025183204A (ja) | 2025-12-16 |
| IL290685A (en) | 2022-04-01 |
| BR112022003539A2 (pt) | 2022-05-24 |
| CN114630673A (zh) | 2022-06-14 |
| EP4025243A4 (en) | 2023-09-27 |
| CA3152379A1 (en) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12364765B2 (en) | Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria | |
| US20220290116A1 (en) | Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels | |
| Stuhlinger et al. | Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst (e) ine and endothelial dysfunction | |
| Gottlieb et al. | Cardioprotection requires taking out the trash | |
| Park et al. | Mitochondrial swelling and microtubule depolymerization are associated with energy depletion in axon degeneration | |
| KR20200096798A (ko) | 윌슨병을 치료하기 위한 비스-콜린 테트라티오몰리브데이트 | |
| Sandri | New findings of lysosomal proteolysis in skeletal muscle | |
| Rudolph et al. | Coronary plaque injury triggers neutrophil activation in patients with coronary artery disease | |
| Wypasek et al. | Factors influencing quality of anticoagulation control and warfarin dosage in patients after aortic valve replacement within the 3 months of follow up | |
| Kawamoto et al. | An association of 5, 10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism and common carotid atherosclerosis | |
| Argalious et al. | Association of testosterone replacement therapy and the incidence of a composite of postoperative in-hospital mortality and cardiovascular events in men undergoing noncardiac surgery | |
| RU2833879C1 (ru) | Терапия с использованием фермента цистатионин-бета-синтазы для лечения заболеваний, вызываемых повышенными уровнями гомоцистеина | |
| RU2839909C2 (ru) | Пэгилированная цистатионин-бета-синтаза для ферментотерапии для лечения гомоцистинурии | |
| HK40071277B (en) | Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria | |
| HK40071277A (en) | Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria | |
| Endo et al. | Beneficial effects of mitochondria-targeted S-nitrosothiol on outcomes after cardiac arrest and resuscitation in rats | |
| Zhan et al. | Serum angiotensin I-converting enzyme levels and the therapeutic effects of octreotide in esophageal variceal hemorrhage | |
| Cucchiara et al. | Carotid dissection causing occipital lobe infarction | |
| Pinna et al. | Decreased plasma cysteinylglycine and taurine levels in branch retinal vein occlusion | |
| Khalil et al. | 39 INTERACTION OF DULOXETINE HYDROCHLORIDE WITH WARFARIN CAUSING PERSISTENT, SEVERE ELEVATION OF INTERNATIONAL NORMALIZED RATIO. | |
| Ranjith | Serum homocysteine levels in cerebrovascular accidents | |
| Tobin et al. | Rare Genetic Causes of Stroke | |
| Herrmann et al. | World Congress on Hyperhomocysteinemia | |
| Almaguer-Mederos et al. | MONDAY, JUNE 6, 2011 LOCATION: SOUTH BUILDING, LEVEL 800, HALL E | |
| Menéndez-Carreño et al. | Correlación entre los productos de oxidación de colesterol (COPs) formados por autooxidación y factores de riesgo cardiovascular |